Immunoexpression and prognostic role of hTERT and cyclin D1 in urothelial carcinoma

APMIS

Volumn 116, Issue 4, 2008, Pages 309-16

  Yang, Ching Hsiu ^a   Hung, Wen Chun ^b   Wang, Sheng Lan ^a,c   Kang, Wan Yi ^a,c   Chen, Wan Tzu ^a   Huang, Ya Chun ^c   Su, Yue Chiu ^a   Chai, Chee Yin ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cyclin D1; hTERT; Immunohistochemistry; Urothelial carcinoma

Indexed keywords

CYCLIN D1; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TUMOR VOLUME; URINARY TRACT CANCER;

EID: 41849130630     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2008.00905.x     Document Type: Article

References (51)

1. Catto JW, Azzouzi AR, Rehman I, Feeley KM, Cross SS, Amira N, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005 23 : 2903 10.
2. Hartmann A, Zanardo L, Bocker-Edmonston T, Blaszyk H, Dietmaier W, Stoehr R, et al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res 2002 62 : 6796 802.
3. Iborra I, Solsona E, Casanova J, Ricos JV, Rubio J, Climent MA. Conservative elective treatment of upper urinary tract tumors: a multivariate analysis of prognostic factors for recurrence and progression. J Urol 2003 169 : 82 5.
4. Catto JW, Yates DR, Rehman I, Azzouzi AR, Patterson J, Sibony M, et al. Behavior of urothelial carcinoma with respect to anatomical location. J Urol 2007 177 : 1715 20.
5. Blackburn EH. Structure and function of telomeres. Nature 1991 350 : 569 73.
6. Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res 1995 55 : 2533 6.
7. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994 266 : 2011 5.
8. Rhyu MS. Telomeres, telomerase, and immortality. J Natl Cancer Inst 1995 87 : 884 94.
9. Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE, et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997 17 : 498 502.
10. Hiyama E, Hiyama K, Yokoyama T, Shay JW. Immunohistochemical detection of telomerase (hTERT) protein in human cancer tissues and a subset of cells in normal tissues. Neoplasia 2001 3 : 17 26.
11. Kanaya T, Kyo S, Takakura M, Ito H, Namiki M, Inoue M. hTERT is a critical determinant of telomerase activity in renal-cell carcinoma. Int J Cancer 1998 78 : 539 43.
12. Liu Y, Snow BE, Hande MP, Yeung D, Erdmann NJ, Wakeham A, et al. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol 2000 10 : 1459 62.
13. Tomoda R, Seto M, Tsumuki H, Iida K, Yamazaki T, Sonoda J, et al. Telomerase activity and human telomerase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors. Cancer 2002 95 : 1127 33.
14. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998 58 : 4168 72.
15. Yang S, Zhang B, Wang J, Liao S, Han J, Wei J, et al. Monoclonal antibodies against human telomerase reverse transcriptase (hTERT): preparation, characterization, and application. Hybridoma 2001 20 : 249 55.
16. Nugent CI, Lundblad V. The telomerase reverse transcriptase: components and regulation. Genes Dev 1998 12 : 1073 85.
17. Tomlinson RL, Ziegler TD, Supakorndej T, Terns RM, Terns MP. Cell cycle-regulated trafficking of human telomerase to telomeres. Mol Biol Cell 2006 17 : 955 65.
18. Greider CW. Telomerase activity, cell proliferation, and cancer. Proc Natl Acad Sci USA 1998 95 : 90 2.
19. Hunter T, Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 1994 79 : 573 82.
20. Sherr CJ. Cancer cell cycles. Science 1996 274 : 1672 7.
21. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997 57 : 1634 7.
22. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, et al. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999 5 : 2069 76.
23. Kuo MY, Lin CY, Hahn LJ, Cheng SJ, Chiang CP. Expression of cyclin D1 is correlated with poor prognosis in patients with areca quid chewing-related oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 1999 28 : 165 9.
24. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer 2001 84 : 270 5.
25. Wagner U, Suess K, Luginbuhl T, Schmid U, Ackermann D, Zellweger T, et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 1999 188 : 44 50.
26. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Requena MJ, et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 2004 122 : 444 52.
27. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon : TARC, 2004.
28. Wang SL, Chen WT, Wu MT, Chan HM, Yang SF, Chai CY. Expression of human telomerase reverse transcriptase in thyroid follicular neoplasms: an immunohistochemical study. Endocr Pathol 2005 16 : 211 8.
29. Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003 114 : 241 53.
30. Gasser SM. A sense of the end. Science 2000 288 : 1377 9.
31. Kyo S, Masutomi K, Maida Y, Kanaya T, Yatabe N, Nakamura M, et al. Significance of immunological detection of human telomerase reverse transcriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase. Am J Pathol 2003 163 : 859 67.
32. Bonatz G, Frahm SO, Klapper W, Helfenstein A, Heidorn K, Jonat W, et al. High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid adenocarcinoma of the uterus. Hum Pathol 2001 32 : 605 14.
33. Tahara H, Yasui W, Tahara E, Fujimoto J, Ito K, Tamai K, et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 1999 18 : 1561 7.
34. Volm M, Mattern J, Koomagi R. Association of telomerase expression with successful heterotransplantation of lung cancer. Int J Oncol 2000 16 : 31 5.
35. Wada H, Enomoto T, Yoshino K, Ozaki K, Kurachi H, Nomura T, et al. Immunohistochemical localization of telomerase hTERT protein and analysis of clonality in multifocal vulvar intraepithelial neoplasia. Am J Clin Pathol 2000 114 : 371 9.
36. Ohyashiki K, Ohyashiki JH, Nishimaki J, Toyama K, Ebihara Y, Kato H, et al. Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay. Cancer Res 1997 57 : 2100 3.
37. Wu A, Ichihashi M, Ueda M. Correlation of the expression of human telomerase subunits with telomerase activity in normal skin and skin tumors. Cancer 1999 86 : 2038 44.
38. Liu K, Hodes RJ, Weng N. Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J Immunol 2001 166 : 4826 30.
39. Lantuejoul S, Soria JC, Moro-Sibilot D, Morat L, Veyrenc S, Lorimier P, et al. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br J Cancer 2004 90 : 1222 9.
40. Malaska J, Kunicka Z, Borsky M, Sklenickova M, Novotna M, Fajkusova L, et al. Telomerase as a diagnostic and predictive marker in colorectal carcinoma. Neoplasma 2004 51 : 90 6.
41. Martin JA, DeYoung BR, Gitelis S, Weydert JA, Klingelhutz AJ, Kurriger G, et al. Telomerase reverse transcriptase subunit expression is associated with chondrosarcoma malignancy. Clin Orthop Relat Res 2004 117 : 24.
42. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004 64 : 1655 63.
43. Park TW, Riethdorf S, Riethdorf L, Loning T, Janicke F. Differential telomerase activity, expression of the telomerase catalytic sub-unit and telomerase-RNA in ovarian tumors. Int J Cancer 1999 84 : 426 31.
44. Baykal A, Rosen D, Zhou C, Liu J, Sahin AA. Telomerase in breast cancer: a critical evaluation. Adv Anat Pathol 2004 11 : 262 8.
45. Widschwendter A, Muller HM, Hubalek MM, Wiedemair A, Fiegl H, Goebel G, et al. Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol 2004 93 : 407 16.
46. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecol Oncol 2005 98 : 396 402.
47. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995 9 : 1149 63.
48. Shin KY, Kong G, Kim WS, Lee TY, Woo YN, Lee JD. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer 1997 75 : 1788 92.
49. Niehans GA, Kratzke RA, Froberg MK, Aeppli DM, Nguyen PL, Geradts J. G1 checkpoint protein and p53 abnormalities occur in most invasive transitional cell carcinomas of the urinary bladder. Br J Cancer 1999 80 : 1175 84.
50. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994 369 : 669 71.
51. Jagadeesh S, Banerjee PP. Telomerase reverse transcriptase regulates the expression of a key cell cycle regulator, cyclin D1. Biochem Biophys Res Commun 2006 347 : 774 80.